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We would like to thank Drs. Janet Woodcock, Robert Califf, and Richard Schilsky for their 
thoughtful comments on our review article.1 When the editors of Clinical Trials solicited our review 
on the U.S. Food and Drug Administration’s (FDA) expedited development and review programs, 
we anticipated there would be accompanying commentaries from other academics with differing 
opinions, or perhaps from the perspectives of industry or venture capital. We hardly expected to 
initiate a discussion among the former Commissioner of the FDA, the current Director of the 
Center for Drug Evaluation and Research (CDER), and the Chief Medical Officer of the American 
Society of Clinical Oncology on the advantages and disadvantages to patients and clinicians of 
FDA’s expedited approval programs. But we appreciate the opportunity to have done so. To be 
clear, the goal of our review was to engage in constructive dialogue, discussing the implications of 
expedited approval programs on premarket and postmarket evidence generation, highlighting some 
specific concerns, and offering our recommendations for robust medical product evaluations that 
ensure high-quality clinical evidence is available to inform patient care and clinical decision-making.  
The FDA faces the challenging task of striking the right balance between ensuring that novel 
therapeutics are safe and effective and allowing promising new drugs to enter the market as quickly 
as possible. We agree with Dr. Califf that FDA’s regulatory approach should not ‘revert back to the 
strategy of the 1970s’.2 Likely in response to the desires frequently expressed by patients and 
clinicians, the U.S. Congress has enacted laws requiring the FDA to develop expedited development 
and review pathways to accelerate the availability of novel therapeutics. Some of these pathways 
necessarily offer potential flexibility with respect to the evidentiary standards that are required to 
demonstrate medical product safety and effectiveness and secure approval. Accordingly, we believe 
there is a need for corresponding efforts to strengthen the clinical evidence that is generated after 
market approval.1   
 
Premarket flexibility and robust postmarket evidence generation 
Over the last decade, the expedited development and review programs have increasingly led 
to products being approved on the basis of fewer or less robust studies.3 As we outline in our 
review,1 this trend corresponds with FDA’s adoption of a ‘lifecycle evaluation’ strategy, where the 
assumption is that once certain drugs are approved, additional safety and efficacy data will be 
generated in the postmarket setting.4 However, there is currently significant variation in the quantity 
and quality of postmarket clinical evidence for therapeutics approved on the basis of limited 
premarket evidence.5-7 We believe that additional efforts are necessary to strengthen postmarket 
clinical evidence generation, in particular for drugs approved via the Accelerated Approval pathway 
on the basis of surrogate markers of disease.  
Dr. Woodcock states that ‘the real issue requiring discussion is how frequently’ failures of 
trials to confirm endpoints used for accelerated approval (i.e., surrogate markers) should occur.8 This 
question warrants significant debate and the answer will likely differ among regulators, industry, 
clinicians, patients, and the research community. One recent study demonstrated that fewer than 5% 
of new drug indications approved by the FDA on the basis of surrogate markers of disease are 
followed by at least one randomized, controlled, double blind postmarket trial published in the peer-
reviewed literature, after an average of 5.5 years, that shows superior efficacy for the same clinical 
indication on the basis of clinical outcomes.7 Even more recently, FDA scientists published a review 
of all new drugs indicated for the treatment of malignant hematology and oncology diseases 
approved by the FDA over the last 25 years using the Accelerated Approval pathway.9 This review 
found 40% of the indications do not have completed confirmatory trials and 5% of the indications 
have been withdrawn.9 Although a 5% withdrawal rate appears to be reasonable for drugs that target 
unmet medical needs, these results imply that for 45% of accelerated cancer drug approvals, benefits 
assumed on the basis of surrogate markers have yet to be, or were not, confirmed.9 
Recently, concerns have been raised about the FDA’s lack of enforcement and drug 
sponsors’ lack of completion of required confirmatory trials.5, 10, 11 Drug sponsors play an important 
role in generating postmarket clinical evidence. However, it is possible that once drug sponsors 
receive an Accelerated Approval for their product, the incentives to generate additional evidence, 
which may undermine previous efficacy and safety claims, may be minimal.6 Furthermore, drug 
sponsors are often performing trials in other therapeutic areas in parallel with their FDA-approved 
indications,6 which may indicate that sponsors prioritize new approvals instead of pursuing 
additional research focused on the originally-approved indications. In order to ensure that 
postmarket clinical evidence is generated, some have called for greater reliance on FDA’s existing 
enforcement authority, including fines and other penalties on sponsors.10  
Although our review recommended that the predictive validity of surrogate markers should 
be assessed using a three-part process,12 as Drs. Woodcock and Schilsky note in their commentaries, 
randomized controlled trials are difficult to conduct for diseases that lack effective treatments.8, 13 
We agree with Dr. Califf about the importance of working ‘together to devise trial designs that are 
informative and acceptable to patients in the postmarket phase.’2 Although we outline certain 
limitations related to using real-world evidence and non-clinical trial data sources to support 
regulatory decisions, we also recognize their potential and suggest ways these study designs can help 
effectively and efficiently address questions that are unanswered at the time of approval.1 For 
instance, rigorous pragmatic clinical trials, which leverage patient data from electronic health records 
or clinical registries, can be a valuable source of postmarket clinical evidence.14 However, we agree 
with Dr. Schilsky that real-world evidence should be used as a complement to clinical trial data, not 
as a substitute, for drug evaluation.13 As we continue moving into an era where expedited 
development and review programs are leveraged to secure earlier market approval, and real-world 
data are increasingly available for research and evaluation efforts, our interests are focused on how 
to strengthen the clinical evidence that is generated after market approval to inform patient care and 
clinical decision-making.  
 
Clarifications and comments 
Dr. Woodcock states that ‘contrary to the assertions of Wallach et al., Fast Track designation 
does not entitle designated drugs ‘to be approved based on a single phase 2 study’ nor influence 
approval standards in any way, and Fast Track drugs do not receive priority review or ‘accelerated 
approval’ unless otherwise eligible for it on their merits’.8 To be clear, our intention was to convey 
that ‘when an agent receives Fast Track designation, it can still be eligible for Accelerated Approval 
and Priority Review,’1 not that one designation leads to the other. Further, we did not think that our 
claim about Fast Track designation allowing therapeutic agents to be approved based on a single 
phase 2 study was controversial. Previous articles discussing Fast Track designation have included 
similar statements15, 16 and our review of the 1998 “Guidance for Industry: Fast Track Drug 
Development Programs – Designation, Development, and Application Review,” under section IV 
(“Programs For Expediting Development and Review”)17 suggested the same, stating: 
 
“…the first phase 2 controlled trials in life-threatening or severely debilitating illnesses may provide sufficient 
data on safety and effectiveness to support approval, with later development of more extensive safety data, dose response 
information, and other information in post marketing studies.” 
 
While more recent guidance documents, including “Guidance for Industry: Expedited Programs for 
Serious Conditions – Drugs and Biologics”,18 do not include similar statements, neither do they 
establish that these prior standards are no longer acceptable.  
 In addition, we appreciated Dr. Woodcock’s clarification that all New Drug Applications ‘are 
required by law to contain all information and studies that sponsoring companies have conducted or 
are aware of.’8 The language we used in our review, suggesting that ‘it is possible that drug sponsors 
only submit individual trials with the largest treatment effects to the FDA’,1 was poorly worded. 
Rather, what we had intended to suggest is that perhaps it is possible that controlled trials with larger 
treatment effect sizes, selected from among all studies submitted by the sponsoring company, are 
more likely to be designated as pivotal and support the product’s approval. To our knowledge, this is 
an empirical question that has not been examined. 
Dr. Woodcock also questioned our summary of the evidence suggesting that expedited 
regulatory approvals were associated with an increased likelihood of the FDA taking safety-related 
actions after market approval. Of the 3 studies we discussed, including one led by FDA scientists 
examining every new small molecule approval between 1997 and 2009,19 priority review and 
expedited pathway approvals were consistently associated with specific safety actions.19-21 Dr. 
Woodcock referenced a new study by Pinnow and other FDA scientists, published after we had 
submitted our review to Clinical Trials, that found no relationship between review times and 
subsequent safety label changes.22 However, the authors of that study note that ‘differences in 
statistical modeling likely explain’ the differences between the previous and present studies.22 
Overall, we believe that the preponderance of evidence suggests that safety-related actions by the 
FDA are more likely among therapies that receive expedited approval. Nevertheless, these findings 
do not necessarily suggest that expedited regulatory approvals are ‘dangerous’. On the contrary, 
when approvals are based on fewer or less robust premarket studies, it is expected that new and 
important information will be learned only after market approval, particularly with respect to safety. 
In some respects, it is reassuring to have found that FDA took major safety-related actions for one-
third of recent novel therapeutic approvals,21 as it suggests that the agency is actively engaging in 
postmarket safety surveillance efforts and acting upon and communicating with clinicians and 
patients when concerns are identified and deemed serious. Continued collaborations between the 
FDA, industry, clinicians, patients, and the research community are needed to ensure that medical 
product safety evaluations are routinely and rigorously conducted after marketing approval.   
Dr. Schilsky discusses how improvements in the field of precision medicine have allowed for 
more accurate identification of patients likely to benefit from a targeted drug.13 We agree that trial 
participants should reflect the population of patients that are expected to benefit from the 
therapeutic agent being evaluated.1 However, it is also worth noting that precision medicine enables 
drugs to be approved for narrower indications based on smaller trials. While these more ‘precise’ 
approvals can effectively address unmet medical needs, there are potential concerns as well if the 
drugs are then prescribed for broader indications, beyond those formally evaluated by the FDA. 
Postmarket clinical evaluations will be needed to understand whether drugs are being appropriately 
used and to confirm their safety and effectiveness in real-world settings.23  
Furthermore, as Dr. Woodcock states in her commentary, many Breakthrough Therapies 
designations arise from drug sponsors focusing on ‘targeted therapies’ or ‘precision medicine’.8 
Considering that ‘more-than-expected’ Breakthrough Therapy designations have been made and that 
a number of Breakthrough Therapy ‘designated drugs have been approved based on early results, 
and with short review times,’8 it will be important to closely monitor the products designated as 
Breakthrough Therapies and determine how often postmarket clinical evaluations are performed and 
the strength of the evidence generated.  
In conclusion, although our review partly focused on the limitations of FDA’s expedited 
development and review programs, we agree with Dr. Califf that ‘the cup is half-full’.2 The FDA has 
a successful track record of working with industry, clinicians, patients, and the research community 
to advance the public’s health by helping to speed innovations that make medicines more accessible, 
while simultaneously working to assure the safety and efficacy of all medical products for which it 
maintains oversight. While expedited approval programs offer the FDA continued opportunities to 
build upon its prior premarket regulatory innovations, there are also opportunities for the agency to 
lead efforts that ensure robust medical product evaluations are taking place after market approval so 
that high-quality clinical evidence is available to inform patient care and clinical decision-making.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
 
1. Wallach JD, Ross JS and Naci H. FDA's expedited approval programs: Evidentiary 
standards, regulatory trade-offs, and potential improvements. Clin Trials 2018, in press. 
2. Califf R. Expedited and facilitated drug evaluations and evidence of benefit and risk: The 
cup is half-full. Clin Trials 2018, in press. 
3. Downing NS, Aminawung JA, Shah ND, et al. Clinical trial evidence supporting FDA 
approval of novel therapeutic agents, 2005-2012. JAMA 2014; 311: 368-377.  
4. Psaty BM, Meslin EM and Breckenridge A. A lifecycle approach to the evaluation of FDA 
approval methods and regulatory actions: opportunities provided by a new IOM report. JAMA 
2012; 307: 2491-2492.  
5. Naci H, Smalley KR and Kesselheim AS. Characteristics of preapproval and postapproval 
studies for drugs granted accelerated approval by the US Food and Drug Administration. JAMA 
2017; 318: 626-636.  
6. Naci H, Wouters OJ, Gupta R, et al. Timing and characteristics of cumulative evidence 
available on novel therapeutic agents receiving Food and Drug Administration accelerated approval. 
Milbank Q 2017; 95: 261-290.  
7. Pease AM, Krumholz HM, Downing NS, et al. Postapproval studies of drugs initially 
approved by the FDA on the basis of limited evidence: systematic review. BMJ 2017; 357: j1680.  
8. Woodcock J. Expediting drug development for serious illness: Trade-offs between patient 
access and certainty. Clin Trials 2018, in press. 
9. Beaver JA, Howie LJ, Pelosof L, et al. A 25-year experience of US Food and Drug 
Administration accelerated approval of malignant hematology and oncology drugs and biologics: A 
review. JAMA Oncol. Epub ahead of print 1 March 2018. DOI: 10.1001/jamaoncol.2017.5618. 
10. Woloshin S, Schwartz LM, White B, et al. The fate of FDA postapproval studies. N Engl J 
Med 2017; 377: 1114-1117.  
11. Fain K, Daubresse M and Alexander GC. The Food and Drug Administration Amendments 
Act and postmarketing commitments. JAMA 2013; 310: 202-204.  
12. Ciani O, Buyse M, Drummond M, et al. Time to review the role of surrogate end points in 
health policy: State of the art and the way forward. Value Health 2017; 20: 487-495.  
13. Schilsky R. Access versus evidence: the regulators’ dilemma. Clin Trials 2018, in press. 
14. Califf RM, Robb MA, Bindman AB, et al. Transforming evidence generation to support 
health and health care decisions. N Engl J Med 2016; 375: 2395-2400.  
15. Kesselheim AS, Wang B, Franklin JM, et al. Trends in utilization of FDA expedited drug 
development and approval programs, 1987-2014: cohort study. BMJ 2015; 351: h4633.  
16. Chary KV. Expedited drug review process: Fast, but flawed. J Pharmacol Pharmacother 2016; 7: 
57-61.  
17. U.S. Food and Drug Administration (FDA). Guidance for industry: Fast track drug 
development programs - Designation, development, and application review. September 
1998, https://www.fda.gov/ohrms/dockets/98fr/980813gd.pdf (1998, accessed 10 March 2018). 
18. U.S. Food and Drug Administration (FDA). Guidance for industry: Expedited programs for 
serious conditions - Drugs and biologics. May 2014, 
www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.
pdf (2014, accessed 10 March 2018). 
19. Schick A, Miller KL, Lanthier M, et al. Evaluation of pre-marketing factors to predict post-
marketing boxed warnings and safety withdrawals. Drug Saf 2017; 40: 497-503.  
20. Mostaghim SR, Gagne JJ and Kesselheim AS. Safety related label changes for new drugs 
after approval in the US through expedited regulatory pathways: retrospective cohort study. BMJ 
2017; 358: j3837.  
21. Downing NS, Shah ND, Aminawung JA, et al. Postmarket safety events among novel 
therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA 
2017; 317: 1854-1863.  
22. Pinnow E, Amr S, Bentzen SM, et al. Postmarket safety outcomes for new molecular entity 
(NME) drugs approved by the Food and Drug Administration between 2002 and 2014. Clin 
Pharmacol Ther.  Epub ahead of print 20 December 2017. DOI: 10.1002/cpt.944. 
23. Wallach JD and Ross JS. Gabapentin approvals, off-label use, and lessons for postmarketing 
evaluation efforts. JAMA 2018; 319: 776-778.  
 
